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Key Points:  
 
- Rac1 and Cdc42 possess non-redundant roles in preventing apoptosis of NPM-ALK 
lymphoma cells 
 
- Simultaneous deletions of both Rac1 and Cdc42 prevents NPM-ALK lymphoma 
dissemination in vivo  
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ABSTRACT 
 
Increasing evidences suggest that Rho family GTPases could have a critical role in the biology of T 
cell lymphoma. In ALK-rearranged anaplastic large cell lymphoma (ALCL), a specific subtype of T 
cell lymphoma, the Rho family GTPases Cdc42 and Rac1 are activated by the ALK oncogenic 
activity. In vitro studies have shown that Cdc42 and Rac1 control rather similar phenotypes of 
ALCL biology such as the proliferation, survival and migration of lymphoma cells. However, their 
role and possible redundancy in ALK-driven lymphoma development in vivo are still undetermined. 
We genetically deleted Cdc42 or Rac1 in a mouse model of ALK-rearranged ALCL to show that 
either Cdc42 or Rac1 deletion impaired lymphoma development, modified lymphoma morphology, 
actin filament distribution and migration properties of lymphoma cells. Cdc42 or Rac1 deletion 
primarily affected survival rather than proliferation of lymphoma cells. Apoptosis of lymphoma 
cells was equally induced following Cdc42 or Rac1 deletion, was associated with upregulation of 
the pro-apoptotic molecule Bid and was blocked by Bcl2 overexpression. Remarkably, Cdc42/Rac1 
double deletion, but not Cdc42 or Rac1 single deletions, completely prevented NPM-ALK 
lymphoma dissemination in vivo. Thus, Cdc42 and Rac1 have non-redundant roles in controlling 
ALK-rearranged lymphoma survival and morphology but are redundant for lymphoma 
dissemination, suggesting that targeting both GTPases could represent a preferable therapeutic 
option for ALCL treatment. 
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INTRODUCTION 
 
The Rho GTPases family members Cdc42 and Rac1 are thought to act as oncogenes in several 
cancer types by regulating proliferation, survival, migration and invasion 1-4. Although initial 
studies suggested that GTPases could act as oncogenes in cancer, recent studies unveiled a tumor 
suppressor rather than oncogenic function for Cdc42 in some tumors 1. In lymphoma and leukemia, 
Rho GTPases are more commonly activated by indirect mechanisms, such as increased Rho 
guanine nucleotide exchange factor (GEF) and/or decreased Rho GTPase-activating protein (GAP) 
activity 4,5, or inactivated by mutations in T cell lymphoma 6-8. ALK-rearranged Anaplastic Large 
Cell Lymphoma (ALCL) is a subtype of T cell lymphoma where the oncogenic translocation t(2;5) 
generates the constitutively active tyrosine kinase NPM-ALK 9,10. NPM-ALK increases the activity 
of Cdc42 and Rac1 by activating the RhoGEFs Vav1 and Vav3, respectively 11,12, thus suggesting 
that Cdc42 and Rac1 could act as oncogenes in ALCL. Indeed, previous in vitro studies in ALCL 
demonstrated that Cdc42 is essential for cell proliferation and survival 9, whereas Rac1 is 
implicated in cell migration of ALK-transformed cells 10. In accordance with these roles, the 
blockade of Cdc42 activity by shRNA knock-down or by pharmacologycal inhibition with 
secramine induced cell cycle arrest and apoptosis of ALCL cells 9, whereas Rac1 inhibiton by the 
NSC23766 inhibitor abrogated NPM-ALK-elicited disease progression and metastasis in mice 13.  
Despite these evidences, however, the specific roles of Cdc42 and Rac1 in ALK-rearranged 
lymphoma development and dissemination in vivo have never been investigated at the genetic level. 
In the present work, we genetically ablated Cdc42 or Rac1 in a mouse model of NPM-ALK-driven 
lymphoma. By this approach, we show that Cdc42 or Rac1 are equally essential for ALCL 
development in vivo, because the deletion of either of them delays NPM-ALK lymphoma 
development by reducing the survival of lymphoma cells. Unexpectedly, Cdc42 or Rac1 single 
deletions have no effect on the dissemination potentials of NPM-ALK lymphoma cells in vivo. In 
contrast, Cdc42/Rac1 double deletions further impair lymphoma development and completely 
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abrogate lymphoma dissemination in vivo. Thus, we demonstrate essential but non-redundant roles 
for Cdc42 and Rac1 in NPM-ALK lymphoma development and dissemination, and suggest that 
effective therapies to target these GTPases in lymphoma should aim at inhibiting both Cdc42 and 
Rac1 simultaneously to achieve a maximal therapeutic effect.  
 
METHODS 
 
Mice and immortalized cell lines 
CD4-NPM-ALK, CD4Cre13, Cdc42fl/fl 14 and Rac1fl/fl 15 alleles have been previously described. 
Briefly, mice containing the Rac1 and/or Cdc42 gene flanked by loxP sites (Rac1fl/Cdc42fl) were 
crossed with NPM-ALK transgenic mice carrying the CD4Cre transgene. All animal experiments 
were approved by the Ethical Committees of the University of Torino as appropriate and performed 
in accordance with the guidelines stated in the International Guiding Principles for Biomedical 
Research Involving Animals, developed by the Council for International Organizations of Medical 
Sciences (CIOMS). Cdc42fl/fl, Rac1fl/fl or Cdc42fl/fl/Rac1fl/fl cell lines were established from 
genetically corresponding tumors that developed in NPM-ALK transgenic mice by serial passaging 
as previously described 13. Cell lines were maintained in RPMI 1640 (Lonza) with 10% (FBS), 2% 
penicillin, streptomycin 5 mg/ml, (Gibco) and 1% glutamine (Gibco). Cell lines were grown at 
37°C in humidified atmosphere with 5% CO2.   
 
In vivo experiments 
NOD scid gamma (NSG) immunocompromised mice were purchased from Charles River 
Laboratories. For tumor dissemination analysis mice were inoculated intravenously (i.v.) with 
5x106 lymphoma cell lines in 0.2 ml of PBS. The lymphoma cell lines used for the in vivo 
experiments are the following: NPM-ALK, NPM-ALK-CD4Cre-Cdc42fl/fl and NPM-ALK-
CD4Cre-Rac1fl/fl, either uninfected or transduced with CreERT2/Bcl2 retroviruses. 15 days after the 
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inoculation mice were sacrificed under anesthesia. All the organs were isolated and immediately 
fixed in formalin solution for histopathological examination (H&E staining).  
 
Retrovirus preparation and cell transduction 
Retroviruses were generated by transient transfection of pWZLblast vector expressing CreERT2 or 
MSCV-EGFP vector carrying Bcl2 in 293 Phoenix packaging cells. After 24h of incubation at 37o 
C, supernatants containing viral particles were collected and used for further transduction.  For the 
retroviral transduction, 300 µl of supernants were used to infect 5x104 lymphoma cells as 
previously described 13. CreERT2 transduced cells were selected using blasticidin (Calbiochem, San 
Diego, CA, USA) at 25 µg/ml for 6 days. Bcl2 transduced cells were analyzed for GFP expression 
by a FACSCalibur flow cytometer (Becton Dickinson). The CELLQuest software was used for data 
acquisition and analysis. 
 
Flow cytometry 
Pre-tumoral thymuses characterization. Mice were sacrificed at 6 weeks of age and pre-tumoral 
thymuses were resected and used for flow cytometry analysis. Single cell suspensions were 
prepared from fresh pre-tumoral thymuses with mechanic disaggregation and isolated by using 40 
μm nylon cell strainer (BD Biosystems, San Jose, CA, USA). Cells were resuspended in phosphate 
saline buffer and stained with the following antibodies: rat anti-mouse CD4-PE (clone GK1.5; 
Miltenyi Biotec) and anti-mouse CD8a-PerCP (clone 53-6.7; BioLegend).  
Immunophenotype. Immortalized cell lines and freshly isolated cells obtained by tumors of NPM-
ALK, NPM-ALK-CD4Cre-Cdc42fl/fl  and NPM-ALK-CD4Cre-Rac1fl/fl transgenic mice were 
incubated and stained with the following antibodies: CD3-FITC, CD4-PE, CD25-APC, 
CD45R(B220)-PE, CD90-PE, NKp46-FITC (all from Milteny Biotec), and CD8a-PerCP 
(BioLegend).  Cells were analyzed in a FACSCalibur flow cytometer (BD Bioscience) using the 
FlowJo software. 
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Immunohistochemical analyses 
Immunohistochemical studies were conducted on formalin-fixed (10%), paraffin-embedded (FFPE) 
tissues. Paraffin sections (2 μm thick) were processed for either H&E staining or 
immunohistochemistry. Images were acquired with an Olympus BX41 microscope equipped with 
2x and 40x objectives.  For immunostainings, anti-ALK (clone 18-0266 , Zymed), anti-Ki-67 (clone 
Sp6, Abcam) and activated caspase 3 antibodies (clone 5A1E, Cell Signaling) were used. Spleen 
sections with reactive lymphoid hyperplasia were employed for positive and negative controls.  
 
Immunofluorescence staining 
Cells were grown for 12 hours on glass coverslips pretreated with fibronectine (10 μg/mL PBS) at 
37°C for 1 hour to facilitate cell adhesion. Samples were fixed in PBS containing 4% 
paraformaldehyde at room temperature for 10 minutes and permeabilized with PBS containing 
0.3% Triton X-100 for 5 minutes. Coverslips were incubated with PBS containing 3% bovine serum 
albumin (BSA) for 1 hour at room temperature and then stained with phycoerythrin (PE)–
conjugated phalloidin (1:200 PBS; Sigma) for 40 minutes in order to stain actin filaments. Nuclei 
were stained 10 minutes at room temperature with HOECHST (300 ng/mL; Sigma). Coverslips 
were mounted in antifading solution and viewed using a Leica photomicroscope. Images were 
acquired at room temperature by means of a 100×/1.40 OIL PL APO objective (Leica, Heidelberg, 
Germany) and analyzed by DM LM Leica software. 
 
Apoptosis assay and cell cycle analysis 
Cells (5x105 cells/ml) were grown in 6-well plates after treatment with 10nM 4-hydroxytamoxifen 
(4-OHT; Sigma) for 4 hours. 1x105 cells were then washed with PBS and incubated for 15 minutes 
at 37°C in annexin V binding buffer containing 200nM tetrametylrodamine methyl-ester (TMRM). 
Percentage of apoptotic cells was analyzed by FACSCalibur flow cytometer (BD Bioscience) using 
CellQuest Program. For DNA content determination, cells were washed with PBS, resuspended in 
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citric acid buffer (0.05 M Na2HPO4, 25 mM sodium citrate, 0.1% Triton X-100; pH 7,3), treated 
with RNase (0.25 mg/mL) and then stained with propidium iodide (50 μg/mL). The S-phase 
fraction was calculated using the Modfit program from Becton Dickinson. 
  
Immunoblotting 
About 40 μg of protein extracts obtained from cell lysates using GST-FISH buffer (10mM MgCl2, 
150mM NaCl, 1% NP40, 2% Glycerol, 1mM EDTA, 25mM HEPES pH 7.5) supplemented with 
1mM PMSF, 10mM NaF, 1mM Na3VO4 (Sigma) and a cocktail of protease inhibitors (Roche), was 
separated on SDS-PAGE (Bio-Rad), transferred to a nitrocellulose membrane, and blotted with 
primary antibodies raised against NPM-ALK (1:3000, Invitrogen), actin (1:4000, Sigma), Cdc42 
(1:3000, BD transduction laboratories), Rac1 (1:4000, Upstate), Bcl2 (1:4000, Santa Cruz 
biotechnology), Bid, Bax, Bik, Bad, Bak, Bim, Puma and cleaved caspase 3 (1:1000, Cell Signaling 
Technology). Secondary anti mouse or anti rabbit were purchased from Amersham.  
 
Migration assays 
Migration assay was performed using Transwell® Permeable Supports (0,8 μm pore size; Corning) 
on 24 well multiplate. Cells were serum starved in RPMI 1640 containing 0.1% FBS and then 
placed in the upper chamber of the Transwell at a concentration of 1x106 cells/well in 100 ul of 
medium. Stromal-derived factor-1 α (SDF-1α; R&D Systems, Minneapolis, USA) was added at the 
bottom of the chamber as a chemoattractant at a concentration of 100ng/ml in serum-free medium. 
After 3 hours of incubation at 37°C in a 5% CO2 atmosphere, the Transwells were removed (with 
non-migrating cells) and the number of the migrated cells was counted. The percentage of migrating 
cells was calculated as ratio to the controls treated with serum-free medium. 
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Statistical analysis 
Statistical significance was calculated with t-Student test, and only values lower than 0.05 were 
considered significant. Tumor free survival distribution was estimated by the nonparametric 
Kaplan-Meier method.  Unless otherwise indicated, data are represented as mean±sd.  
 
 
RESULTS  
 
Rac1 and Cdc42 possess non-redundant roles in NPM-ALK mediated lymphomagenesis 
To study the functions of Cdc42 and Rac1 in NPM-ALK rearranged lymphoma in vivo, we deleted 
Cdc42 or Rac1 genes in NPM-ALK transgenic (Tg) mice that develop ALK-driven T cell 
lymphoma with high penetrance 14. Constitutive deletions of either Cdc42 15 or Rac1 16 are 
embryonic lethal, whereas T-cell specific deletions of Cdc42 or Rac1 are associated with modest 
impairment of T cell development and functions 17-19. To achieve a T cell restricted deletion, we 
crossed conditional Cdc42fl/fl or Rac1fl/fl mice with CD4Cre mice that express the Cre recombinase 
in both CD4 and CD8 T cells under the control of the CD4 minimal promoter 20. By this approach 
we aimed at deleting Cdc42 or Rac1 simultaneously with the induction of NPM-ALK expression, 
because NPM-ALK expression is under the control of the same CD4 promoter 14. Indeed, we 
obtained an efficient deletion of Cdc42 or Rac1 in the large majority of thymocytes as demonstrated 
by an almost complete loss of protein expression by Western Blot (Figure 1A). Deletion of Cdc42 
or Rac1 in the thymus resulted only in a slight impairment of T cell maturation with decreased 
numbers of single positive CD4+ or CD8+ T cells, a phenotype that was more pronounced in 
CD4Cre-Cdc42fl/fl mice (Supplementary Figure 1 and Supplementary Table 1). These results are 
comparable to previous studies where Rac1 or Cdc42 deletions were mediated by Lck-Cre 17,19 or 
hCD2-Cre 18. In contrast, double deletions of Cdc42 and Rac1 have never been described to our 
knowledge. By crossing CD4Cre mice with Cdc42fl/fl/Rac1fl/fl mice, we achieved an efficient double 
 10
deletion of both Cdc42 and Rac1 (Figure 1A). In these mice, we observed a significant reduction in 
thymocyte numbers with a relative decrease in the CD4+/CD8+ double positive population 
(Supplementary Figure 1 and Supplementary Table 1).  
To study the effects of Cdc42 or Rac1 on NPM-ALK mediated lymphomagenesis, we crossed 
NPM-ALK transgenic mice with CD4Cre-Cdc42fl/fl or CD4Cre-Rac1fl/fl mice. Deletion of Cdc42 or 
Rac1 was efficient and T cell development was comparable to NPM-ALK negative mice (Figure 
1A, Supplementary Figure 1 and Supplementary Table 1), with a slight increase in mature CD4+ or 
CD8+ T cells in NPM-ALK transgenic mice as we previously described 14. Expression of NPM-
ALK in T cells acts as a strong driver oncogene, as 100% of mice develop lymphoma, with a mean 
survival of 15 weeks 14. NPM-ALK lymphomas arose in both NPM-ALK/CD4Cre/Cdc42fl/fl and 
NPM-ALK/CD4Cre/Rac1fl/fl mice despite the efficient deletion of Cdc42 or Rac1 in all tumor tested 
(10 NPM-ALK/CD4Cre/Cdc42fl/fl, 10 NPM-ALK/CD4Cre/Rac1fl/fl) (Figure 1B and Supplementary 
Table 2). Strikingly, however, deletion of either Cdc42 or Rac1 significantly delayed lymphoma 
onset and extended survival (Figure 1C). NPM-ALK/CD4Cre/Cdc42fl/fl/Rac1fl/fl mice (n=17) did not 
develop lymphoma up to 28 weeks (Figure 1D). Unfortunately, longer follow-up was not reached as 
Cdc42/Rac1 double knock-out mice died prematurely because of multiorgan failure currently under 
investigation.  
 
In vivo deletion of Cdc42 or Rac1 increase apoptosis of NPM-ALK lymphoma cells 
Deletions of Cdc42 or Rac1 did not substantially change the frequency of tumor subtypes or the 
phenotype of lymphoma developed in NPM-ALK transgenic mice alone. T cell lymphoma was by 
far the predominant tumor subtype developed in each genetic strain (Supplementary Table 2), in 
accordance with our previous report 14. The phenotype of NPM-ALK lymphoma was mostly 
negative for both CD4 and CD8, or weakly positive for CD4, corresponding to an early stage of T 
cell development when the CD4 transgene is activated to expressed NPM-ALK (Supplementary 
Figure 2), as we previously described 14. By morphology, NPM-ALK/CD4Cre/Cdc42fl/fl and NPM-
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ALK/CD4Cre/Rac1fl/fl lymphomas were comparable to NPM-ALK lymphomas, with lymphoma 
cells showing smaller size and rounder morphology (Figure 2A-B). Interestingly, NPM-
ALK/CD4Cre/Cdc42fl/fl and NPM-ALK/CD4Cre/Rac1fl/fl tumors showed comparable proliferation 
index but significantly higher apoptotic rate than NPM-ALK tumors (Figure 2C-D). Overall these 
data indicated that Cdc42 or Rac1 deletion changed the morphology and decreased cell viability, 
but not the proliferation, of NPM-ALK transformed lymphoma cells.  
 
Deletions of Cdc42 or Rac1 induce a Bcl2 dependent apoptosis in NPM-ALK lymphoma cells 
To better characterize the mechanistic role of Rac1 and Cdc42 in NPM-ALK mediated 
lymphomagenesis, we generated NPM-ALK lymphoma cell lines where genetic Cdc42 or Rac1 
deletions could be induced at will. Immortalized lymphoma cell lines with different genotypes 
(NPM-ALK, NPM-ALK/Cdc42fl/fl, NPM-ALK/Rac1fl/fl and NPM-ALK/Rac1fl/fl/Cdc42fl/fl) were 
transduced with a retrovirus expressing an inducible CreERT2 construct that allows the activation of 
the Cre-recombinase upon treatment with 4-hydroxytamoxifen (4-OHT). By this system, efficient 
deletions were achieved within 48 hours of initial treatment with 4-OHT (10nM for 4 hours) in 
single Cdc42fl/fl or Rac1fl/fl, as well as in double Cdc42fl/fl/Rac1fl/fl lymphoma cells (Figure 3A). 
Single deletions of Cdc42 or Rac1 significantly impaired cell growth of NPM-ALK lymphoma cells 
compared to cells with functional Cdc42 and Rac1 (Figure 3B). A similar growth reduction was 
observed in Cdc42/Rac1 double knock-out (DKO) lymphoma cells (Figure 3B). Consistent with the 
in vivo findings, Cdc42 or Rac1 deletions induced only a slight reduction in the proliferation of 
lymphoma cells as measured by S-phase and cell cycle (Supplementary Figure 3). In contrast, 
single deletions of Cdc42 or Rac1 were associated with a potent induction of cell apoptosis (Figure 
3C and Supplementary Figure 4), which was consistent with the increased apoptosis observed in 
primary tumors (Figure 2D). Surprisingly, Cdc42/Rac1 DKO showed a phenotype comparable to 
single Cdc42 or Rac1 KOs without additional effects on the cell cycle or apoptosis (Figure 3C and 
Supplementary Figures 3-4). Next, we further investigated the mechanisms of apoptosis induced by 
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Cdc42 or Rac1 deletions. To this end, we exploited our system of inducible Cdc42 or Rac1 
deletions in NPM-ALK lymphoma cells to perform a screening for key factors involved in 
apoptosis. We found a strong upregulation of the BH3 interacting-domain death agonist Bid in 
single Cdc42 or Rac1 KOs as well as in Cdc42/Rac1 DKO, whereas no changes were observed in 
the pro-apoptotic NPM-ALK target Bim 21,22 or in other key mediators of apoptosis (Figure 3A). 
Bid interacts with Bax to induce apoptosis by increasing the permeability of mitochondria and can 
be counteracted by Bcl2 23. Therefore, we reasoned that overexpression of Bcl2 would prevent Bid-
mediated apoptosis in Cdc42- or Rac1-deleted as well as in Cdc42/Rac1 DKO lymphoma cells. To 
test this hypothesis, we overexpressed Bcl2 in NPM-ALK lymphoma cells (Figure 4A). Bcl2 
overexpression completely blocked Bid upregulation and Caspase 3 activation upon deletion of 
Cdc42 or Rac1 as well as in DKO cells (Figure 4A). Consistently, apoptosis of NPM-ALK 
lymphoma cells induced by Cdc42 or Rac1 deletions was markedly reduced (Figure 4B and 
Supplementary Figure 4). 
 
Redundant roles of Cdc42 and Rac1 in NPM-ALK lymphoma dissemination 
We previously reported that Cdc42 activation directly governs the NPM-ALK lymphoma cell shape 
(i.e. the anaplastic morphology) 11, whereas a similar effect for Rac1 activation has not been studied 
yet. Thus, we decided to precisely address this question by taking advantage of our system of 
inducible genetic deletion of Cdc42 or Rac1. Cell morphology can be properly evaluated by 
analyzing the distribution of F-actin filaments within the cytoplasm of anaplastic lymphoma cells, 
where F-actin is unevenly distributed and polarized. The pattern of actin polarization directly 
reflects the activity of NPM-ALK on the cytoskeleton and is mediated by Cdc42 11. As expected, 
deletion of Cdc42 significantly reduced the irregular shape and actin polarization of NPM-ALK 
lymphoma cells (Figure 5A), as cells became more regularly rounded (Figure 5B), smaller (Figure 
5C) and lost F-actin polarization (Figure 5D). Remarkably, Rac1 deletion induced comparable 
changes in NPM-ALK lymphoma cell morphology, thus indicating that both Cdc42 and Rac1 
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control lymphoma cell morphology (Figure 5). Simultaneous deletions of both Cdc42 and Rac1 
further increased the phenotype of loss of polarization (Figure 5 B and D), indicating similar but 
non-redundant roles in regulating NPM-ALK lymphoma cells shape. Finally, we asked whether 
Cdc42 or Rac1 were critical for NPM-ALK lymphoma cell migration and dissemination in vivo. 
First, we tested lymphoma migration in vitro to confirm that Cdc42 or Rac1 deletions resulted in 
reduced cell migration, as expected from previous works 11,12. Cdc42/Rac1 DKO lymphoma cells 
showed a comparable impairment of migration (Figure 6A). Next, we studied in vivo dissemination 
of NPM-ALK lymphoma. For this experiment, we generated cell lines with stable deletions of 
Cdc42 or Rac1 after 4-OHT induction of CreERT2-recombinase, by expressing Bcl2 to block 
apoptosis as shown above. Indeed, cell lines with stable CreERT2-induced Cdc42 or Rac1 deletion 
showed comparable deletion efficacy and similar growth rates to cell lines immortalized from 
transgenic mice that express CD4Cre (Supplementary Figure 5A-B). Importantly, this approach 
allowed us to generate stable Cdc42/Rac1 DKO cell lines, as DKO lymphomas were never obtained 
in transgenic mice (Figure 1D). Cdc42/Rac1 DKO NPM-ALK lymphoma cell lines showed 
comparable growth rates to singly Cdc42 or Rac1 deleted lymphoma cell lines (Supplementary 
Figure 5). Equal numbers of NPM-ALK cells were injected intravenously in recipient mice and 
lymphoma dissemination was analyzed in various organs 2 weeks after cell injection. Control 
NPM-ALK lymphoma cells completely colonized lymphoid organs, such as spleen and lymph 
nodes, as well as several other organs including liver, kidneys and lungs (Figure 6 and 
Supplementary Table S3). The presence and dissemination of NPM-ALK lymphoma cells was 
confirmed by ALK immunostaining (Supplementary Figure 6). NPM-ALK lymphoma cells with 
single deletion of Cdc42 or Rac1 - either by CD4Cre or CreERT2 - equally disseminated to the same 
organs, whereas lymphoma cells with Cdc42/Rac1 DKO were almost completely unable to 
disseminate and colonize lymphoid and non-lymphoid organs (Figure 6, Supplementary Figure 6 
and Supplementary Table S3). Overall, these results show that Cdc42 and Rac1 control cell shape 
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and migration of NPM-ALK lymphoma cells. However, only a simultaneous elimination of Cdc42 
and Rac1 activities can prevent lymphoma dissemination in vivo.  
 
 
DISCUSSION 
 
Anaplastic Large Cell Lymphoma (ALCL) has peculiar morphologic features compared to most T 
and non-T cell lymphomas. They have a highly atypical morphology and peculiar patterns of 
dissemination 9,24. Previous reports showed that in ALK-rearranged ALCL the oncogenic NPM-
ALK directly controls cell shape and migration of lymphoma cells by activating the Rho GTPases 
Cdc42 and Rac1 11-13. Mechanistically, NPM-ALK directly phosphorylates the RhoGEFs Vav1 and 
Vav3 to activate in turn Cdc42 and Rac1, respectively 11,12. Recent work showed that NPM-ALK 
also exploits the Tiam1 RhoGEF to activate Rac1 via phosphatidylinositol 5-phosphate (PtdIns5P) 
produced by the PI 5-kinase PIKfyve 25. NPM-ALK not only activates Cdc42 and Rac1 but appears 
to regulate a larger program of GTPase activity regulation that also involves RhoA inhibition 11, 
thus suggesting that in NPM-ALK driven lymphoma Cdc42 and Rac1 could act as oncogenes, 
whereas RhoA could represent a tumor suppressor.  This view is corroborated by recent studies that 
found RhoA frequently inactivated by mutations in peripheral T cell lymphoma 6-8 and Burkitt 
Lymphoma 26.  
In this work, we developed a genetic approach to specifically delete Cdc42 or Rac1 in T cells 
transformed by the NPM-ALK oncogenic activity. In addtion, we also deleted simultaneously 
Cdc42 and Rac1 in the same lymphoma cells, a feat never accomplished before. By this approach, 
we showed that Cdc42 or Rac1 deletions delayed to a comparable extent the onset of NPM-ALK 
driven lymphoma in mice. Cdc42/Rac1 double deleted NPM-ALK mice never developed 
lymphoma, but the follow-up was relatively short due to the early lethality in these mice. The 
causes of this early lethality are not yet understood and currently under investigation in our 
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laboratory. By necropsy studies carried out in most of the mice, we could not detect any evidence 
for lymphoma or plasma cells tumors, but rather signs of multiorgan failure that involved the liver, 
kidneys and lungs.   
In vivo deletion of Cdc42 or Rac1, as well as in vitro through an inducible system, was associated 
mostly with an increased apoptotic rate of lymphoma cells, with relatively mild effects on the cell 
cycle and proliferation. Thus, by this genetic approach we could determine that Cdc42 and Rac1 
control survival rather than proliferation of lymphoma cells, a conclusion partially in contrast with 
previous studies based on shRNA knock-downs or not specific inhibitors such as secramine for 
Cdc42 11 or NSC23766 for Rac1 13. In our genetically deleted models, a predominant role for Cdc42 
or Rac1 on survival was further supported by results in lymphoma cell lines where apoptosis was 
blocked by overexpression of Bcl2. Indeed, in the presence of high levels of Bcl2, Cdc42 or Rac1 
deleted NPM-ALK cell lines showed a similar proliferation rate to lymphoma cells with normal 
expression of Cdc42 or Rac1, thus further supporting the conclusion that lymphoma proliferation is 
only marginally dependent on the activity of Cdc42 or Rac1 in NPM-ALK lymphoma. The 
signaling network activated by Cdc42 and Rac1 is extremely complex. Antiapoptotic and survival 
signals activated by Cdc42 or Rac1 include NF-kB, p38/MAPK, mTOR as well as other molecules 
that greatly overlap with targets activated by NPM-ALK itself 2,9,10. In addition to an involvement 
in cell survival or proliferation, Cdc42 or Rac1 have well-established roles to govern cell 
movements, migration and metastasis formation 1-3. As expected by previous studies from our group 
and others 11,12, we found that either Cdc42 or Rac1 deletion was associated to a reduction of cell 
migration in vitro induced by the chemokine SDF-1. Surprisingly, however, neither Cdc42 nor 
Rac1 single deletions impaired lymphoma migration and dissemination in vivo. NPM-ALK 
lymphoma cells deleted for Cdc42 or Rac1 efficiently colonized not only lymphoid organs such as 
the spleen and the bone marrow, but also non-lymphoid organs such as liver, kidneys and lungs. In 
contrast, when both Cdc42 and Rac1 were simultaneously deleted, NPM-ALK lymphoma cells lost 
completely their capacity of in vivo dissemination despite retaining a similar proliferation rate 
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(Figure 5 and Supplementary Figures 5 and 6). These results indicate that for in vivo dissemination 
NPM-ALK lymphoma cells can compensate for the loss of function of one GTPase but not both, 
thus indicating that Cdc42 and Rac1 have non-redundant roles in NPM-ALK driven lymphoma 
growth but are redundant for lymphoma dissemination. In alternative to redundancy, it is possible 
that double Cdc42 and Rac1 deletion could act with a threshold mechanism because we observed 
more dramatic changes in cell morphology and F-actin filament distribution in Cdc42/Rac1 double 
deleted lymphoma cells compared to single deletions. In this view, only a more profound loss of 
GTPase activity as in double Cdc42 and Rac1 deleted cells would result in an impairment of cell 
migration in vivo.  
Overall, these results could have substantial therapeutic implications as the interest in developing 
Cdc42 or Rac1 inhibitors for clinical use is constantly growing 2,27. Our data indicate that a 
simultaneous inhibition of both Cdc42 and Rac1 would likely have a more profound effect on 
lymphoma growth and dissemination. As dual Cdc42/Rac1 inhibitors have been recently developed 
and are currently tested in pre-clinical mouse models 28, this approach could represent a potential 
additional therapeutic strategy for NPM-ALK lymphoma. 
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TABLES 
 
 
Table 1.  In vivo NPM-ALK lymphoma dissemination  
Genotype 
 
Cre Spleen Liver Kidney Lung 
Bone 
marrow 
Brain Heart 
NPM-ALK CD4Cre 4/4 4/4 4/4 4/4 4/4 0/4 0/4 
NPM-ALK;Cdc42fl/fl CD4Cre 3/3 3/3 3/3 3/3 3/3 0/3 0/3 
NPM-ALK;Rac1fl/fl CD4Cre 3/3 3/3 3/3 3/3 3/3 0/3 0/3 
NPM-ALK;Cdc42fl/fl CreERT2 3/3 3/3 3/3 0/3 3/3 0/3 0/3 
NPM-ALK;Rac1fl/fl CreERT2 3/3 3/3 3/3 2/3 3/3 0/3 0/3 
NPM-ALK;Cdc42fl/fl;Rac1fl/fl CreERT2 0/6 0/6 0/6 1/6 0/6 0/6 0/6 
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FIGURE LEGENDS 
Figure 1. Deletion of Cdc42 or Rac1 impair NPM-ALK lymphoma development in vivo  
(A) Representative Western Blots of Cdc42 and Rac1 deletion in pre-tumoral thymuses obtained 
from WT or NPM-ALK transgenic mice. Mice were sacrificed at 4 weeks of age when lymphoma 
was not phenotypically and morphologically detectable as previously described 12. Cell lysates were 
extracted and membranes were blotted with the indicated antibodies. (B) Representative Western 
Blots for Cdc42 and Rac1 deletion in primary tumors from mice with the indicated genotype. Three 
tumors out of 10 analyzed for each genotype are shown. (C-D) Kaplan-Meier survival curves of 
NPM-ALK transgenic mice in presence or absence of Cdc42 and/or Rac1. NPM-ALK mice were 
crossed with mice carrying the indicated conditional knocked-in alleles. All mice were analyzed by 
necropsy to demonstrate the presence of lymphoma: NPM-ALK (n=70), NPM-
ALK;CD4Cre;Cdc42fl/fl (NPM-ALK/Cdc42KO; n=25), NPM-ALK;CD4Cre;Rac1fl/fl (NPM-
ALK/Rac1KO; n=58), NPM-ALK;CD4Cre;Cdc42fl/fl;Rac1fl/fl (NPM-ALK/Cdc42/Rac1KO; n=17).  
 
Figure 2. Apoptosis induced by Cdc42 or Rac1 deletion impairs NPM-ALK lymphoma 
development in vivo 
(A) Representative histology of lymphoma arising in NPM-ALK, NPM-ALK;CD4Cre;Cdc42fl/fl 
(NPM-ALK/Cdc42KO) or NPM-ALK;CD4Cre;Rac1fl/fl (NPM-ALK/Rac1KO) mice (top panels). 
Immunostainings for Ki-67 (mid panels) and activated Caspase 3 (bottom panels) in tumors of the 
indicated genotypes are shown. Scale bar = 50μm. (B) Histograms represent the average diameter 
quantified by counting at least 100 cells for each genotype. Error bars indicated SEM. ***p<0.001. 
(C) Quantification of the percentages of proliferating cells based on Ki-67 counts on sections 
stained by immunohistochemistry. Data were obtained from 10 different areas in 3 independent 
mice for each genotype. (D) Quantification of the percentages of apoptotic cells based on activated 
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Caspase 3 counts on sections stained by immunohistochemistry. Data were obtained from 10 
different areas in 3 independent mice for each genotype.  Error bars indicated SEM. ***p<0.001. 
 
Figure 3. Deletion of Cdc42 or Rac1 increases apoptosis mediated by Bid upregulation 
(A) Representative Western Blots of immortalized NPM-ALK lymphoma cell lines obtained from 
mice with the indicated genotypes. Cells were transduced by retroviruses expressing an inducible 
CreERT2 recombinase system and selected using 6μg/mL blasticidin for 6 days. Cre recombinase 
was shortly activated by treatment with 10nM 4-hydroxytamoxifen (4-OHT) for 4 hours to induce 
deletion of the floxed genes. Cells were collected 24, 48 and 72 hours after 4-OHT induction, lysed 
and blotted with the indicated antibodies. Data are from one representative cell line for each 
genotype out of 3 NPM-ALK, 5 NPM-ALK;CreERT2;Cdc42fl/fl, 4 NPM-ALK;CreERT2;Rac1fl/fl and 
3 NPM-ALK;CreERT2;Cdc42fl/fl;Rac1fl/fl cell lines transduced with CreERT2 recombinase. (B) 
NPM-ALK lymphoma cell lines obtained from mice with the genotypes as in (A) and expressing 
CreERT2 were conditionally deleted of the indicated floxed genes by treatment with 10nM 4-OHT 
for 4 hours as described above. Cell growth/viability were measured by CellTiter-Glo at the 
indicated time points. Data are indicated as mean±sd of triplicate experiments, each performed with 
three independent cell lines for each genotype. (C) Percentages of apoptotic cells measured by 
TMRM staining at the indicated time points in NPM-ALK immortalized lymphoma cells from mice 
with the indicated genotypes after CreERT2 induction of the floxed genes as described above. Data 
are indicated as means+SD of triplicate experiments, each performed with three independent cell 
lines for each genotype.  ***p<0.001.  
 
Figure 4. Bcl2 overexpression blocks apoptosis, Bid upregulation and Caspase 3 activation 
associated with Cdc42 and Rac1 deletion in NPM-ALK lymphoma 
Three independent CreERT2 lymphoma cell lines for each indicated genotype as in Figure 2 were 
transduced with a retrovirus expressing Bcl2 and GFP as reporter. Percentages of transduced cells 
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were calculated by GFP positivity in flow cytometry and were above 90% in all cell lines. Cdc42 
and Rac1 deletions were induced by treatment with 10nM 4-hydroxytamoxifen for 4 hours. (A) 
Cells were collected at the indicated time points, lysed and Western Blots were performed with the 
indicated antibodies. (B) Overexpression of Bcl2 rescues apoptosis induced by Cdc42 or Rac1 
deletion. Three independent CreERT2 lymphoma cell lines for each indicated genotype as in (A) 
were transduced with a retrovirus expressing Bcl2 and GFP. Cdc42 or Rac1 deletion was induced 
by 4-OHT treatment as described above. Analysis of apoptosis was carried out by TMRM staining 
and flow cytometry at the indicated time points. Data are indicated as mean±sd of triplicate 
experiments, each performed with three independent cell lines for each genotype. P values are 
calculated by comparing Ctrl vs 4-OHT induced cells at each indicated time point: ***p<0.001. 
 
Figure 5. Control of NPM-ALK lymphoma cell shape by Cdc42 or Rac1 
NPM-ALK, NPM-ALK;Cdc42fl/fl, NPM-ALK;Rac1fl/fl and NPM-ALK;Cdc42fl/fl;Rac1fl/fl lymphoma 
cell lines were immortalized from primary tumors arising in mice with the indicated genotype. Cells 
were transduced with CreERT2 and Bcl2 retroviruses and then conditionally deleted for the 
indicated floxed genes by treatment with 10nM 4-hydroxytamoxifen for 4 hours as described above. 
Stable cell lines were obtained by culturing deleted cells for at least 3 weeks. (A) Cell morphology 
and cell shape were evaluated by immunofluorescence using phycoerythrin-conjugated phalloidin 
staining to detect actin filaments. Scale bar = 5 μm. NPM-ALK = NPM-ALK;CreERT2, NPM-
ALK/Cdc42KO = NPM-ALK;CreERT2;Cdc42fl/fl;Bcl2, NPM-ALK/Rac1KO = NPM-
ALK;CreERT2;Rac1fl/fl;Bcl2, NPM-ALK/Cdc42/Rac1KO = NPM-ALK;CreERT2; 
Cdc42fl/fl;Rac1fl/fl;Bcl2. (B-D) Histograms represent the percentage of round versus polarized cells 
expressed as cell shape (B), average diameter (C) and as actin distribution around the membrane or 
in the lamellipodial membrane protrusion (D). Each quantification was obtained by counting at least 
100 cells for each condition. Two independent lymphoma cell lines for each genotype were studied 
in triplicate experiments. Error bars indicate SEM. ***p<0.001; **p<0.002; *p<0.05. 
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Figure 6. Effects of Cdc42 and Rac1 deletions on in vitro migration and in vivo dissemination 
of NPM-ALK lymphoma cells 
(A) Three independent CreERT2 lymphoma cell lines for each genotype were transduced with a 
retrovirus expressing Bcl2 to protect cells from apoptosis as in Figure 5. Cdc42 and Rac1 deletions 
were induced by treatment with 10nM 4-hydroxytamoxifen for 4 hours. Cell were then seeded into 
the upper chamber of transwells (0.8µm pore size) and allowed to migrate toward a gradient of 
SDF-1α (100ng/ml) that was plated in the lower chamber for 4 hours in CO2 incubator. Migrated 
cells in the bottom chamber were counted. The histograms indicate means+SD from three 
independent cell lines for each genotype using triplicate wells for experimental point. T test was 
used to calculate statistical significance. *p<0.001. NPM-ALK = NPM-ALK;CreERT2, NPM-
ALK/Cdc42KO = NPM-ALK;CreERT2;Cdc42fl/fl;Bcl2, NPM-ALK/Rac1KO = NPM-
ALK;CreERT2;Rac1fl/fl;Bcl2, NPM-ALK/Cdc42/Rac1KO = NPM-ALK;CreERT2; 
Cdc42fl/fl;Rac1fl/fl;Bcl2 (B) Immortalized NPM-ALK lymphoma cell lines with the genotypes as in 
(A) were inoculated i.v. (5x106) in NOD scid gamma (NSG) mice. After 15 days mice were 
sacrificed and all the organs were isolated and fixed in formalin solution for H&E staining. Figure 
shows representative histology of spleen, liver and kidney. NPM-ALK = NPM-ALK;CreERT2, 
NPM-ALK/Cdc42KO = NPM-ALK;CreERT2;Cdc42fl/fl;Bcl2, NPM-ALK/Rac1KO = NPM-
ALK;CreERT2;Rac1fl/fl;Bcl2, NPM-ALK/Cdc42/Rac1KO = NPM-ALK;CreERT2; 
Cdc42fl/fl;Rac1fl/fl;Bcl2. Scale bar = 1mm. 
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